俄罗斯各地区抗逆转录病毒治疗失败时艾滋病毒耐药性的流行情况

IF 2.8 3区 医学 Q2 INFECTIOUS DISEASES
HIV Medicine Pub Date : 2024-04-07 DOI:10.1111/hiv.13642
Ekaterina Ozhmegova, Aleksey Lebedev, Anastasiia Antonova, Anna Kuznetsova, Elena Kazennova, Kristina Kim, Aleksandr Tumanov, Marina Bobkova
{"title":"俄罗斯各地区抗逆转录病毒治疗失败时艾滋病毒耐药性的流行情况","authors":"Ekaterina Ozhmegova,&nbsp;Aleksey Lebedev,&nbsp;Anastasiia Antonova,&nbsp;Anna Kuznetsova,&nbsp;Elena Kazennova,&nbsp;Kristina Kim,&nbsp;Aleksandr Tumanov,&nbsp;Marina Bobkova","doi":"10.1111/hiv.13642","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>This study aimed to investigate mutations associated with, the causes of, and the conditions that contribute to HIV drug resistance (DR). This research provides crucial insights into the mechanisms through which HIV evades antiretroviral drugs and suggests strategies to counter this phenomenon. Our objective was to assess the prevalence and structure of DR in HIV-1 across various regions in Russia and identify the primary factors influencing the development of HIV DR.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study used nucleotide sequences from the HIV-1 <i>pol</i> gene obtained from 1369 patients with a history of therapy and virological failure between 2005 and 2019 to analyze the frequency and structure of DR and the factors associated with it.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The analysed HIV-1 genotypes included viruses resistant to nucleoside reverse transcriptase inhibitors (NRTIs; 11.8%), non-nucleoside reverse transcriptase inhibitors (NNRTIs; 6.4%), and NRTIs + NNRTIs (31.7%). The mutations M184V/I and G190A/S/E were the most prevalent, accounting for 54.5% and 26.6%, respectively. The dominance of multiple DR persisted throughout the entire observation period. The likelihood of encountering drug-resistant variants was increased among men, patients in the late stage of infection, and those with a viral load &lt;30 000 RNA copies/mL. Injection drug use was not associated with DR.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study has yielded new insights into HIV DR in Russia, offering valuable information to identify clinical or programmatic events warranting closer attention and support.</p>\n </section>\n </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia\",\"authors\":\"Ekaterina Ozhmegova,&nbsp;Aleksey Lebedev,&nbsp;Anastasiia Antonova,&nbsp;Anna Kuznetsova,&nbsp;Elena Kazennova,&nbsp;Kristina Kim,&nbsp;Aleksandr Tumanov,&nbsp;Marina Bobkova\",\"doi\":\"10.1111/hiv.13642\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>This study aimed to investigate mutations associated with, the causes of, and the conditions that contribute to HIV drug resistance (DR). This research provides crucial insights into the mechanisms through which HIV evades antiretroviral drugs and suggests strategies to counter this phenomenon. Our objective was to assess the prevalence and structure of DR in HIV-1 across various regions in Russia and identify the primary factors influencing the development of HIV DR.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The study used nucleotide sequences from the HIV-1 <i>pol</i> gene obtained from 1369 patients with a history of therapy and virological failure between 2005 and 2019 to analyze the frequency and structure of DR and the factors associated with it.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The analysed HIV-1 genotypes included viruses resistant to nucleoside reverse transcriptase inhibitors (NRTIs; 11.8%), non-nucleoside reverse transcriptase inhibitors (NNRTIs; 6.4%), and NRTIs + NNRTIs (31.7%). The mutations M184V/I and G190A/S/E were the most prevalent, accounting for 54.5% and 26.6%, respectively. The dominance of multiple DR persisted throughout the entire observation period. The likelihood of encountering drug-resistant variants was increased among men, patients in the late stage of infection, and those with a viral load &lt;30 000 RNA copies/mL. Injection drug use was not associated with DR.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This study has yielded new insights into HIV DR in Russia, offering valuable information to identify clinical or programmatic events warranting closer attention and support.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13176,\"journal\":{\"name\":\"HIV Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/hiv.13642\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hiv.13642","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景这项研究旨在调查与艾滋病病毒耐药性(DR)相关的突变、产生原因和条件。这项研究有助于深入了解艾滋病病毒逃避抗逆转录病毒药物的机制,并提出应对策略。我们的目标是评估俄罗斯不同地区 HIV-1 中 DR 的流行率和结构,并确定影响 HIV DR 发展的主要因素。方法该研究使用了从 2005 年至 2019 年期间 1369 名有治疗史和病毒学失败史的患者身上获得的 HIV-1 pol 基因核苷酸序列,以分析 DR 的频率和结构以及与之相关的因素。结果分析的HIV-1基因型包括对核苷类逆转录酶抑制剂(NRTIs;11.8%)、非核苷类逆转录酶抑制剂(NNRTIs;6.4%)和NRTIs + NNRTIs(31.7%)耐药的病毒。突变 M184V/I 和 G190A/S/E 最为普遍,分别占 54.5% 和 26.6%。在整个观察期内,多种 DR 变异一直占主导地位。在男性、感染晚期和病毒载量为 30000 RNA拷贝/毫升的患者中,出现耐药变体的可能性增加。结论这项研究为了解俄罗斯艾滋病病毒的耐药性提供了新的视角,为确定值得密切关注和支持的临床或计划事件提供了宝贵的信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia

Background

This study aimed to investigate mutations associated with, the causes of, and the conditions that contribute to HIV drug resistance (DR). This research provides crucial insights into the mechanisms through which HIV evades antiretroviral drugs and suggests strategies to counter this phenomenon. Our objective was to assess the prevalence and structure of DR in HIV-1 across various regions in Russia and identify the primary factors influencing the development of HIV DR.

Methods

The study used nucleotide sequences from the HIV-1 pol gene obtained from 1369 patients with a history of therapy and virological failure between 2005 and 2019 to analyze the frequency and structure of DR and the factors associated with it.

Results

The analysed HIV-1 genotypes included viruses resistant to nucleoside reverse transcriptase inhibitors (NRTIs; 11.8%), non-nucleoside reverse transcriptase inhibitors (NNRTIs; 6.4%), and NRTIs + NNRTIs (31.7%). The mutations M184V/I and G190A/S/E were the most prevalent, accounting for 54.5% and 26.6%, respectively. The dominance of multiple DR persisted throughout the entire observation period. The likelihood of encountering drug-resistant variants was increased among men, patients in the late stage of infection, and those with a viral load <30 000 RNA copies/mL. Injection drug use was not associated with DR.

Conclusion

This study has yielded new insights into HIV DR in Russia, offering valuable information to identify clinical or programmatic events warranting closer attention and support.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
HIV Medicine
HIV Medicine 医学-传染病学
CiteScore
5.10
自引率
10.00%
发文量
167
审稿时长
6-12 weeks
期刊介绍: HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信